Clinical Trial Update: Bevacizumab Against Recurrent Retinal Detachment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bevacizumab for recurrent retinal detachment and proliferative vitreoretinopathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Retinal Detachment

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 | Status: COMPLETED | Results posted: 2021-03-26